Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.

ABSTRACT: It is not well determined whether primary tumor resection is associated with better outcomes in metastatic colorectal cancer (mCRC) patients treated with bevacizumab. In this meta-analysis, we aimed to assess the prognostic role of primary tumor resection in mCRC treated with bevacizumab. Electronic databases including the Cochrane library, Embase, and Pubmed were searched until April 2018. Clinical studies assessing the influence of primary tumor resection on the efficacy of bevacizumab in patients with mCRC were identified. The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). Seven studies including 2760 mCRC patients were finally included. The results of the meta-analysis were in favor of bevacizumab to patients with resected pr

SUBMITTER: Cao D 

PROVIDER: S-EPMC6937309 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature